FDA approves Leo Pharma drug  

2006.01.13
Danish pharmaceutical company Leo Pharma has announced that its drug Taclonex has been approved by the FDA for sale in the US

Danish pharmaceutical company Leo Pharma has announced that its drug Taclonex has been approved by the FDA for sale in the US. Taclonex is a topical treatment of psoriasis in adults and is marketed as Dovobet or Daivobet outside the US. Warner Chilcott, Leo Pharma's exclusive licensee of Taclonex in the US, plans to launch the drug in Q2 2006. Warner Chilcott also has the marketing rights for Leo Pharma's Dovonex in the US, a non-steroidal topical treatment for psoriasis.

Dovonex, which in Europe is sold under the name Daivonex, generated sales of USD 130 m (DKK 803 m) in Europe in 2005. Sales of Taclonex are expected to be at least as high. Paul Herendeen, finance director of Warner Chilcott comments: "We have very high expectations of Taclonex and will launch the product as soon as possible. The two products will make up a very large part of Warner Chilcott's total revenues, and so they have great importance for the future development of the company".

Leo Pharma is headquartered in Ballerup near Copenhagen and employs 3,200 people in more than 40 countries. The pharmaceutical company is one of the world's leaders in dermatology and parenteral treatment of thromboembolic disorders. The news was reported by financial daily newspaper Børsen.

Link > Leo Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×